Larvol Delta - Alumis-plans-to-initiate-a-Phase-2-biomarker-trial-for-A005-its-central-nervous-system-penetrant-TYK2-inhibitor-in-patients-with-Parkinsons-disease-in-the-rst-half-of-2027

A-005 - Alumis

https://www.globenewswire.com/news-release/2026/08/13/3344885/0/en/alumis-reports-second-quarter-2026-financial-results-and-highlights-recent-achievements.html

Aug 13, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next